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To the Editor: We read with 
great interest the article by Xynos et 
al. reporting 2 cases of leishmaniasis 
in patients treated with biologic drugs 
(1). Although we agree with most of 
the article, we are not totally con-
vinced that serologic analysis alone 
could be used to screen for leishma-
niasis before initiation of biologic or 
immunosuppressive treatments. Evi-
dence indicates that serologic analy-
sis can identify only symptomatic or 
asymptomatic cases with recent and 
still active infection (2,3).
Leishmania spp. are pathogens 
that infect hematopoietic cells, where 
they establish chronic intracellular 
parasitism and survive for an infected 
person’s lifetime. In leishmaniasis-
endemic countries, asymptomatic 
visceral leishmaniasis (VL) infections 
occur more frequently than clinical-
ly apparent VL cases. An estimated 
10%–20% of persons with asymp-
tomatic infections develop clinically 
overt VL (4). The leishmanin skin test 
(LST) (Montenegro test), an intrader-
mal injection of a suspension of killed 
promastigotes, measures delayed hy-
persensitivity reactions and appears 
to be the only screening test capable 
of detecting asymptomatic leishmania 
infections.
A positive LST result is thought 
to indicate durable cell-mediated im-
munity after asymptomatic infection 
or clinical cure of VL. LST positivity 
may appear months to years postin-
fection, but once positivity appears, it 
persists in immunocompetent patients. 
A survey of VL in Ethiopia showed 
LST positivity in 32.2% of the popu-
lation, but leishmania antibodies were 
found in only 4.1% (5).
Because different antigen prepa-
rations may affect test sensitivity, LST 
should use promastigotes of the Leish-
mania spp. present in an area. We be-
lieve that ideal screening for leishma-
niasis should include LST along with 
serologic analysis. Unfortunately, little 
data exist on the use of antileishmania 
therapies for LST-positive or serologi-
cally positive patients. VL with unusu-
al signs and symptoms may develop in 
immunocompromised patients with 
previous LST positivity after immu-
nosuppressive treatments. Information 
about LST positivity is useful for call-
ing attention to this potential risk for 
VL that may have unusual manifesta-
tions in these persons.
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In Response: In their letter re-
sponding to our recently published 
article (1) Cascio and Iaria spark an 
important discussion on the useful-
ness of screening for Leishmania in-
fection before administering biologic 
agents or other immunosuppressive 
treatments to patients having autoim-
mune rheumatic diseases and living 
in areas where  Leishmania parasites 
are endemic (2). Although we agree 
in principle that early detection of as-
ymptomatic Leishmania infection will 
decrease the incidence of the disease 
in immunosuppressed patients, current 
diagnostic tools may have a limited (or 
restricted) role in detecting Leishma-
nia infection in this vulnerable patient 
population. Screening for leishmania-
sis has been hampered by the lack of 
a standard test. Currently available 
serologic methods have variable sen-
sitivities, specificities, and cross-reac-
tivities, depending on the species be-
ing tested and the region where tests 
are performed. Many experts believe 
that serologic tests may complement 
other existing diagnostic tools, raising 
cost-efficiency concerns, especially in 
financially deprived countries (3).
A positive leishmanin skin test 
(LST) result indicates exposure to 
Leishmania spp. and is generally 
thought to reflect a durable cell-me-
diated immune response. No cross-
reaction occurs in patients with Cha-
gas disease, but some cross-reactions 
are found in patients with glandular 
tuberculosis or lepromatous leprosy 
(4). Sustained positive responses 
have been documented for up to 20 
years after exposure to the Leishma-
nia parasite. Nevertheless, LST has 
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limitations. In a longitudinal study of 
visceral leishmaniasis in Bangladesh, 
Bern et al. reported loss of LST sensi-
tivity attributed to antigen-production 
issues, such as standardization and 
documentation of sensitivity, potency, 
and stability of leishmanin antigens 
(5). Also, prior treatment with immu-
nosuppressive agents, which influence 
cell-mediated immunity, may decrease 
LST prognostic potency similarly to 
changes observed for the tuberculin 
skin test in similar settings (6).
Variations in specificities and 
sensitivities limit the diagnostic po-
tential of available diagnostic tools. 
The context of immunosuppression 
further contributes to the diagnostic 
complications and increases the need 
for additional research in leishmania-
sis diagnostics.
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ANOTHER DIMENSION
Red Snappers
Erin E. McConnell
for a moment pretend
you are not
the infallible house staff,
but the latest admission—
hacking putrid sputum
from your soulful depths
or your festering chest,
depending on your mood. 
slapped with a mask,
you are secured in secluded rooms;
a paucity of guests,
but for the parade of absurd birds—
plastered in Haz-mat
lemon-yellow gowns,
and peach-colored beaks.
your meager dried-up sleep 
is aborted by 
bloodhungry fowl
covetous of mucus
you no longer produce.
your meals grow cold
waiting for you
in the anteroom of
your negative pressure purgatory.
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